Why build another PI3K inhibitor? | KymaThera #Shorts

▶ Full episode: Why Build Another PI3K Inhibitor? Inside an $80M Bet (youtu.be/wxed0Vdlg6I)

The target already has drugs; K-1728 is built to hit the disease-driving mutant forms and spare the normal one — but that design isn't yet evidence in people

Full breakdown: https://youtu.be/wxed0Vdlg6I

Sources:

[S1] KymaThera／PR Newswire: https://www.prnewswire.com/news-releases/kymathera-announces-80-million-series-b-financing-to-advance-k-1728-a-next-generation-pan-mutant-selective-pi3k-inhibitor-for-cancer-and-vascular-malformations-302899716.html

[S2] MedlinePlus Genetics：PIK3CA: https://medlineplus.gov/genetics/gene/pik3ca/

[S4] KymaThera Pipeline: https://www.kymathera.com/pipeline/

[S5] FDA：Step 3, Clinical Research: https://www.fda.gov/patients/drug-development-process/step-3-clinical-research